{
    "clinical_study": {
        "@rank": "114349", 
        "acronym": "PI13-05", 
        "arm_group": {
            "arm_group_label": "PI 13-05", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the GORE\u00ae PI-13-05 clinical study is to evaluate the safety and\n      efficacy of PI 13-05 for the treatment of arterial occlusive disease in patients with de\n      novo or restenotic lesions in the common and/or external iliac arteries."
        }, 
        "brief_title": "Evaluation of the GORE\u00ae PI 13-05 Device for the Treatment of Occlusive Disease in the Common and External Iliac Arteries", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Common Iliac Artery Occlusion", 
            "External Iliac Artery Occlusion"
        ], 
        "condition_browse": {
            "mesh_term": "Arterial Occlusive Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is at least 18 years old;\n\n          -  Patient is male, infertile female, or female of childbearing potential    practicing\n             an acceptable method of preventing pregnancy;\n\n          -  Patient or legal representative is willing to give written informed   consent;\n\n          -  Patient is capable of complying with protocol requirements, including all follow-up\n             visits;\n\n          -  Patient has symptomatic claudication or rest pain without tissue loss (Rutherford\n             Categories 2-4).\n\n          -  Patient has de novo or restenotic target lesion(s) in the common and/or external\n             iliac artery\n\n        Exclusion Criteria:\n\n          -  Patient has a life expectancy of less than 1 year;\n\n          -  Patient has a known allergy to stent graft components, including stainless steel or\n             heparin;\n\n          -  Patient has a known intolerance to antiplatelet, anticoagulant, or thrombolytic\n             medications that would prevent compliance with the protocol;\n\n          -  Patient has a condition (unrelated to the study) that is expected to require\n             indefinite, or lifelong, anticoagulation\n\n          -  Patient has had vascular access / catheterization in the lower extremity within 30\n             days of study enrollment;\n\n          -  Patient has had a previous or planned coronary intervention within 30 days prior to\n             enrollment in this study or required at time of study procedure; Patient has had a\n             previous or planned bypass surgery in the target leg, or a bypass that occurs at the\n             time of the study procedure;\n\n          -  Patient is currently participating in this or another investigative clinical study.\n\n          -  Patient has evidence of angiographically visible thrombus within or adjacent to the\n             target lesion(s);\n\n          -  Patient has aneurysmal dilation proximal or distal to the target lesion(s) that would\n             interfere with the placement of the device;\n\n          -  Patient has a target lesion requiring atherectomy or any ablative device to\n             facilitate stent delivery;\n\n          -  Patient has a target lesion situated in such a way that an implanted device will\n             prevent blood flow or perfusion to the internal iliac artery if patent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961167", 
            "org_study_id": "Gore PI 13-05"
        }, 
        "intervention": {
            "arm_group_label": "PI 13-05", 
            "intervention_name": "PI 13-05", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Auckland", 
                    "country": "New Zealand"
                }, 
                "name": "Auckland City Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "New Zealand"
        }, 
        "number_of_arms": "1", 
        "official_title": "Feasibility Evaluation of the GORE\u00ae PI 13-05 Device for the Treatment of Occlusive Disease in the Common and External Iliac Arteries", 
        "overall_contact": {
            "last_name": "Angela Wienand", 
            "phone": "+1 928853 8387"
        }, 
        "overall_official": {
            "affiliation": "Auckland City Hospital", 
            "last_name": "Andrew Holden, MB ChB", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "New Zealand: Health and Disability Ethics Committees", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Composite safety endpoint measured as a percentage,tallying all subjects experiencing any of the events as a failure", 
            "safety_issue": "No", 
            "time_frame": "within 30 days of index procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961167"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "W.L.Gore & Associates", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "W.L.Gore & Associates", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}